Latest Eversept Partners, LP Stock Portfolio

Eversept Partners, LP Performance:

2025 Q4: 17.48%YTD: 19.86%2024: 19.98%

Performance for 2025 Q4 is 17.48%, and YTD is 19.86%, and 2024 is 19.98%.

About Eversept Partners, LP and 13F Hedge Fund Stock Holdings

On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Eversept Partners, LP reported an equity portfolio of $2 Billions as of 31 Dec, 2025.

The top stock holdings of Eversept Partners, LP are VERA, GSK, UTHR. The fund has invested 7.8% of it's portfolio in VERA THERAPEUTICS INC and 6.6% of portfolio in GSK PLC.

The fund managers got completely rid off ZIMVIE INC (ZIMV), REPLIGEN CORP (RGEN) and AVIDITY BIOSCIENCES INC (RNA) stocks. They significantly reduced their stock positions in UNIQURE NV (QURE), EVOLUS INC (EOLS) and ARS PHARMACEUTICALS INC (SBTX). Eversept Partners, LP opened new stock positions in EXACT SCIENCES CORP (EXAS), CIDARA THERAPEUTICS INC (CDTX) and BETA BIONICS INC. The fund showed a lot of confidence in some stocks as they added substantially to PENNANT GROUP INC (PNTG), MOLINA HEALTHCARE INC (MOH) and ARCUTIS BIOTHERAPEUTICS INC (ARQT).

Eversept Partners, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Eversept Partners, LP made a return of 17.48% in the last quarter. In trailing 12 months, it's portfolio return was 19.86%.

Performance
S&P 500

New Buys

Ticker	$ Bought
exact sciences corp	24,544,800
cidara therapeutics inc	21,806,500
beta bionics inc	20,666,600
glaukos corp	16,651,000
esperion therapeutics inc ne	14,249,200
select med hldgs corp	13,455,600
cg oncology inc	12,807,500
bristol-myers squibb co	12,691,700

New stocks bought by Eversept Partners, LP

Additions

Ticker	% Inc.
pennant group inc	673
molina healthcare inc	380
arcutis biotherapeutics inc	289
healthequity inc	254
avantor inc	243
maravai lifesciences hldgs i	147
biocryst pharmaceuticals inc	117
humana inc	94.94

Additions to existing portfolio by Eversept Partners, LP

Reductions

Ticker	% Reduced
uniqure nv	-92.84
evolus inc	-76.67
ars pharmaceuticals inc	-74.24
rapport therapeutics inc	-58.74
revvity inc	-58.72
teva pharmaceutical inds ltd	-51.59
regeneron pharmaceuticals	-39.61
illumina inc	-37.97

Eversept Partners, LP reduced stake in above stock

Sold off

Ticker	$ Sold
zimvie inc	-39,383,500
gossamer bio inc	-2,433,360
89bio inc	-5,768,880
avidity biosciences inc	-13,197,800
kura oncology inc	-2,333,110
sutro biopharma inc	-1,989,780
novo-nordisk a s	-12,080,600
repligen corp	-14,047,000

Eversept Partners, LP got rid off the above stocks

Sector Distribution

Eversept Partners, LP has about 77.4% of it's holdings in Healthcare sector.

Sector	%
Healthcare	77.4
Others	20
Basic Materials	2

Market Cap. Distribution

Eversept Partners, LP has about 30% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	31.4
LARGE-CAP	28.2
UNALLOCATED	20
SMALL-CAP	16.6
MEGA-CAP	1.8
MICRO-CAP	1.3

Stocks belong to which Index?

About 52.2% of the stocks held by Eversept Partners, LP either belong to S&P 500 or RUSSELL 2000 index.

Index	%
Others	47.7
RUSSELL 2000	37.7
S&P 500	14.5

Top 5 Winners (%)		%
	structure therapeutics inc	131.1 %
ADGI	invivyd inc	118.6 %
	fortrea hldgs inc	102.6 %
	ceribell inc	90.9 %
TYRA	tyra biosciences inc	86.2 %

Top 5 Winners ($)		$
VERA	vera therapeutics inc	63.4 M
NTRA	natera inc	29.1 M
	abivax sa	27.1 M
SNDX	syndax pharmaceuticals inc	19.1 M
TVTX	travere therapeutics inc	18.5 M

Top 5 Losers (%)		%
ALEC	alector inc	-39.6 %
QURE	uniqure nv	-31.6 %
IFRX	inflarx nv	-24.5 %
NVAX	novavax inc	-19.6 %
PLRX	pliant therapeutics inc	-17.4 %

Top 5 Losers ($)		$
QURE	uniqure nv	-16.2 M
AVTR	avantor inc	-2.1 M
ALEC	alector inc	-1.7 M
PODD	insulet corp	-1.5 M
UNH	unitedhealth group inc	-0.9 M

Eversept Partners, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Eversept Partners, LP

Eversept Partners, LP has 103 stocks in it's portfolio. About 42.6% of the portfolio is in top 10 stocks. QURE proved to be the most loss making stock for the portfolio. VERA was the most profitable stock for Eversept Partners, LP last quarter.

Last Reported on: 17 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
AADI	whitehawk therapeutics inc	0.03	260,259	629,827	new

ACAD	acadia pharmaceuticals inc	0.24	176,594	4,716,830	added	7.52

ADGI	invivyd inc	0.27	2,140,130	5,286,120	added	4.54

ALEC	alector inc	0.08	1,006,160	1,569,610	reduced	-32.41

AMRN	amarin corp plc	0.12	172,188	2,402,880	added	2.94

ANAB	anaptysbio inc	0.30	120,927	5,862,540	new

ANTX	elevance health inc formerly	0.53	30,195	10,584,900	reduced	-32.87

ARDX	ardelyx inc	0.50	1,715,130	9,999,200	added	19.99

ARQT	arcutis biotherapeutics inc	0.64	434,634	12,621,800	added	289

ASMB	assembly biosciences inc	0.27	159,676	5,430,580	new

ASND	ascendis pharma a/s	0.52	48,241	10,286,900	new

AVTR	avantor inc	1.83	3,176,640	36,404,300	added	243

BCRX	biocryst pharmaceuticals inc	1.18	2,992,900	23,344,600	added	117

BCYC	bicycle therapeutics plc	0.06	178,915	1,266,720	reduced	-7.98

BIIB	biogen inc	0.69	77,944	13,717,400	added	50.57

BKD	brookdale sr living inc	0.20	374,929	4,045,480	new

BMRN	biomarin pharmaceutical inc	0.28	93,748	5,571,440	reduced	-36.07

BMY	bristol-myers squibb co	0.64	235,293	12,691,700	new

BRKR	bruker corp	1.86	783,789	36,924,300	added	14.07

BVS	bioventus inc	0.18	471,257	3,506,150	added	8.6